Earnings fall short of analyst expectations
- Regeneron’s stock falls 2.6% after earnings miss estimates
- Net income down 12% from the year-earlier period
- Adjusted earnings below consensus
- Revenue falls 1% below expectations
- Eylea sales decline due to changing market dynamics
- Dupixent treatment sales rise 24%
- Full-year R&D costs and capex guidance increased
- New $3.0 billion share buyback program approved
Regeneron Pharmaceuticals Inc.’s stock fell 2.6% premarket Thursday after the company’s first-quarter profit and revenue fell short of analyst estimates. The net income for the quarter was down 12% from the year-earlier period, and adjusted earnings were below consensus. Revenue also fell 1% below expectations. Eylea sales declined due to changing market dynamics, while sales of the company’s Dupixent treatment rose 24%. The company increased its full-year R&D costs and capex guidance and approved a new $3.0 billion share buyback program.
Factuality Level: 7
Factuality Justification: The article provides specific details about Regeneron Pharmaceuticals Inc.’s first-quarter performance, including net income, earnings, revenue, and sales figures. It also mentions the reasons behind the changes in sales and provides information about the company’s future expectations and plans. However, the article lacks any critical analysis or comparison with industry standards, and it does not provide any expert opinions or external perspectives to validate the information presented.
Noise Level: 2
Noise Justification: The article provides a straightforward report on Regeneron Pharmaceuticals Inc.’s first-quarter financial results, including details on profit, revenue, and sales of key products. It stays on topic and does not contain irrelevant information. The article supports its claims with specific numbers and data. However, it lacks in-depth analysis, accountability, or insights beyond the financial figures.
Financial Relevance: Yes
Financial Markets Impacted: Regeneron Pharmaceuticals Inc.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to the financial performance of Regeneron Pharmaceuticals Inc., with its first-quarter profit and revenue falling short of analyst estimates. There is no mention of an extreme event.
Public Companies: Regeneron Pharmaceuticals Inc. (REGN)
Key People: Leonard S. Schleifer (Chief Executive)
Reported publicly:
www.marketwatch.com 
